The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children
Abstract
Objectives To gain a better understanding of the capacity of psychostimulant medications to induce adverse psychiatric reactions and determine the frequency of such reactions, we analyzed postmarketing surveillance data and clinical trial data for drugs, either approved or under development, for the treatment of attention-deficit/hyperactivity disorder. Methods The US Food and Drug Administration requested manufacturers of drugs approved for attention-deficit/hyperactivity disorder or with active clinical development programs for that indication to search their electronic clinical trial databases for cases of psychosis or mania using prespecified search terms. The manufacturers supplied descriptions of clinical trials, numbers of patients exposed to study drug, and duration of exposure to permit calculations of incidence rates. Independently, cases of psychosis or mania in children and adults for drugs used to treat attention-deficit/hyperactivity disorder from the Food and Drug Administration Adverse Event Reporting System safety database were analyzed. Manufacturers were asked to conduct similar analyses of their postmarketing surveillance databases. Results We analyzed data from 49 randomized, controlled clinical trials in the pediatric development programs for these products. A total of 11 psychosis/mania adverse events occurred during 743 person-years of double-blind treatment with these drugs, and no comparable adverse events occurred in a total of 420 person-years of p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An uncommon significant adverse effect of stimulants is the occurrence of hallucinations and other psychotic symptoms.111”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [111]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Dopamine in schizophrenia: a review and reconceptualization
Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,051
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296
Abuse and toxicity of methylphenidate
Klein‐Schwartz, W. (2002) · Current Opinion in Pediatrics · doi:10.1097/00008480-200204000-00013 · Cited by 168
Ross, R. G. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.7.1149 · Cited by 164
Psychotic Side Effects of Psychostimulants: A 5-Year Review
Cherland, E., & Fitzpatrick, R. (1999) · The Canadian Journal of Psychiatry · doi:10.1177/070674379904400810 · Cited by 100
Lucas, A. R. (1971) · JAMA · doi:10.1001/jama.1971.03190080041008 · Cited by 66
Aggression, Mania, and Hypomania Induction Associated With Atomoxetine
Henderson, T. A., & Hartman, K. (2004) · PEDIATRICS · doi:10.1542/peds.2004-1140 · Cited by 48
Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action.
Jg, Y. (1981) · PubMed · Cited by 39
Cited by
Sorted by citations
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
European guidelines on managing adverse effects of medication for ADHD
(for the European Guidelines Group), Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0140-6 · Cited by 374
Cortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Graham, J., Taylor, E., Sergeant, J., et al. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12036 · Cited by 336
Metadata
- Authors
- Mosholder, A. D., Gelperin, K., Hammad, T. A., Phelan, K., & Johann-Liang, R.
- Affiliations
- United States Food and Drug Administration (US)
- Health Resources and Services Administration, Department of Health and Human Services, Rockville, Maryland
- Corresponding author
- Gelperin, Kate
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2009-02-01
- Volume
- 123
- Issue
- 2
- Pages
- 611-616
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2092853583
- Cited by
- 155
- References
- 15
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 10 · 2023: 4 · 2022: 8 · 2021: 6 · 2020: 15 · 2019: 18 · 2018: 7 · 2017: 10 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 6 · 2012: 8
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- attention deficit hyperactivity disorder, psychostimulants, psychosis, mania, hallucinations, adverse drug reactions, drug safety in children, post-marketing surveillance, FDA Adverse Event Reporting System
- MeSH terms
- Attention Deficit Disorder with Hyperactivity, Child, Female, Hallucinations, Humans, Male, Psychoses, Substance-Induced, Adverse Drug Reaction Reporting Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
